Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1937-1938

  Pini, Tunghi M ^a   Griffin, Marie R ^b,d   Roumie, Christianne L ^b   Huizinga, Mary Margaret ^c   Fowke, Jay H ^f   Greevy, Robert ^e   Liu, Xulei ^e   Murff, Harvey J ^b,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FINASTERIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; VETERAN;

COHORT STUDIES; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 67449085153     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0215     Document Type: Article

References (11)

1. Cancer facts & figures 2008. American Cancer Society.
2. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9. (Pubitemid 28048654)
3. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-1983 (Pubitemid 44664277)
4. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147-152 (Pubitemid 40096789)
5. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic USmen , 2001-2002. Am J Epidemiol 2006;164:978-983
6. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR γ ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 2004;4:465-477
7. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res 2000;60:5494-5498 (Pubitemid 30761263)
8. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A 2000;97:10990-10995 (Pubitemid 30751266)
9. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-711 (Pubitemid 41071191)
10. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993;22:31-37 (Pubitemid 23075491)
11. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174:877-881 (Pubitemid 41140621)